Feedback
Settings

Settings

Goto Application

2,045 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(SFFCQAIBJUCFJK-UGKPPGOTSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 205
1.20250375390Method of Lyophilisation
US - 11.12.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 19298524 Applicant GlaxoSmithKline Biologicals SA Inventor Frédéric MATHOT

The present invention provides lyophilised pharmaceutical compositions and methods of making said lyophilised pharmaceutical compositions. More particularly, the present invention provides lyophilised pharmaceutical compositions comprising nucleic acid and lipid carrier particles and methods of making said lyophilised pharmaceutical compositions. The provided lyophilised compositions have improved critical quality attributes (CQAs) and the provided methods prevent the need for a deep-freeze cold chain. The present invention further provides the use of said lyophilised pharmaceutical compositions in medicine.

2.WO/2025/255393HERPES SIMPLEX VIRUS ANTIGEN BINDING AGENTS FOR MITIGATION OF HERPES SIMPLEX VIRUS ASSOCIATED DISEASE
WO - 11.12.2025
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
 Appl.No PCT/US2025/032531 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor COHEN, Gary H.
Provided herein are compositions for the prevention and treatment of genital herpes, comprising antigen binding agents to herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, ribonucleic acids (RNAs) encoding these antigen binding agents, and methods of use thereof.
3.20250375391LIPID NANOPARTICLE COMPOSITIONS COMPRISING SURFACE LIPID DERIVATIVES AND RELATES USES
US - 11.12.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 19099108 Applicant ModernaTX, Inc. Inventor Yue HUI

The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a neutral polymer surface lipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.

4.20250376534CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA
US - 11.12.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No 18876542 Applicant Orna Therapeutics, Inc. Inventor Thomas Barnes

Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

5.20250375389LIPID NANOPARTICLE COMPOSITIONS COMPRISING PHOSPHOLIPID DERIVATIVES AND RELATED USES
US - 11.12.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 19099092 Applicant ModernaTX, Inc. Inventor Jaclyn MILTON

The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a phosphatidylserine phospholipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.

6.2025539366遺伝子編集構築物の標的化送達及びその使用方法
JP - 05.12.2025
Int.Class A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
 Appl.No 2025530058 Applicant ザ　トラスティーズ　オブ　ザ　ユニバーシティ　オブ　ペンシルバニア Inventor ハミデ　パーヒズ
本発明は、遺伝子編集剤を標的細胞に効果的に送達するための組成物及び疾患又は障害を治療するためのその使用方法に関する。
【選択図】 図１Ａ
7.20250367128BIODEGRADABLE LIPIDOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF FOR LIVER TARGETED DELIVERY
US - 04.12.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 18853162 Applicant The Trustees of the University of Pennsylvania Inventor Michael Mitchell

Described are biodegradable lipid nanoparticles (LNPs) comprising biodegradable lipidoids and compositions thereof. In various embodiments, the LNP selectively targets a liver cell. In other aspects, the present invention relates to methods for in vivo delivery of therapeutic nucleic acids to the liver to prevent or treat diseases or disorders using the LNP compositions of the invention.

8.WO/2025/250751CIRCULAR RNA COMPOSITIONS AND METHODS
WO - 04.12.2025
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
 Appl.No PCT/US2025/031358 Applicant ORNA THERAPEUTICS, INC. Inventor EMMANUEL, Akinola
Circular RNA, along with related compositions, methods, and precursor RNA, are described herein. In some embodiments, the composition comprises a transfer vehicle and a circular RNA comprising a 3' self-spliced exon segment, a translation initiation element (TIE), an expression sequence encoding a chimeric antigen receptor (CAR), and a 5' self-spliced exon segment. In some embodiments, the transfer vehicle comprises an ionizable lipid disclosed herein. In some embodiments, the circular RNA and/or composition thereof has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life as compared to linear RNA. Also presented herein are methods and compositions for the manufacture and preparation of circularized RNAs, along with methods of administering said circular RNAs and related compositions to a subject in need thereof for treatment or prevention purposes.
9.20250367240DERIVATION OF GLUCOSE-RESPONSIVE INSULIN-SECRETING CELLS AND ORGANOIDS FROM HUMAN STOMACH CELLS AND THEIR USE TO TREAT DIABETES
US - 04.12.2025
Int.Class A61K 35/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
37Digestive system
39Pancreas; Islets of Langerhans
 Appl.No 18870864 Applicant CORNELL UNIVERSITY Inventor Qiao Joe ZHOU

The present disclosure is directed to a method of producing human gastric insulin-secreting (GINS) cells and human gastric insulin-secreting (GINS) organoids. The present disclosure provides a population of human gastric insulin-secreting (GINS) cells and a preparation of human gastric insulin-secreting (GINS) organoids, which are glucose-responsive and insulin-secreting. The present disclosure also provides methods of controlling glycemia in a human subject by transplanting to the human subject the population of human GINS cells or the preparation of human GINS organoids.

10.WO/2025/242026CANCER VACCINES AND USES THEREOF
WO - 27.11.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/CN2025/095665 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor XIE, Liang
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express two or more cancer antigens. Also provided herein are methods for treating a cancer.
# -